Physician profile
Daniel K Files
NPI 1083051841
$15,967.96
in general payments reported to CMS, 2019-2025
69 companies · $3,277 in 2025
The $3,277 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,639 · 2020: $1,440 · 2021: $2,305 · 2022: $2,427 · 2023: $2,484 · 2024: $2,396 · 2025: $3,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,156.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,330.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,638.80 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $1,632.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,164.73 | 2019-2025 | |
| Lilly USA, LLC | $674.52 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $598.65 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $586.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.27 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $468.25 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $464.93 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $441.99 | 2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.01 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $330.04 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $298.87 | 2019-2023 | Ztlido |
| Astellas Pharma US INC | $292.50 | 2019-2025 | Veozah, Myrbetriq |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $281.83 | 2024-2025 | Fanapt |
| Lundbeck LLC | $250.23 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $228.26 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.54 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $218.61 | 2019-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $201.11 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $184.31 | 2022 | |
| Abbott Laboratories | $176.84 | 2022-2024 | Proclaim |
| Janssen Pharmaceuticals, INC | $150.37 | 2019-2024 | Spravato |
| Verona Pharma, INC. | $137.41 | 2025 | Ohtuvayre |
| Allergan, INC. | $136.39 | 2019-2020 | |
| Exact Sciences Corporation | $128.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $120.30 | 2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $101.75 | 2022-2024 | |
| Corium, LLC | $96.51 | 2023-2024 | Azstarys, Adlarity, Azstarys |
| Novartis Pharmaceuticals Corporation | $94.36 | 2019-2022 | |
| Corcept Therapeutics | $88.46 | 2023-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $84.91 | 2019-2020 | |
| Eisai INC. | $74.51 | 2019-2021 | |
| Almatica Pharma LLC | $71.72 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $67.83 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $64.86 | 2023-2024 | Inspire |
| Dexcom, INC. | $61.88 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $55.66 | 2024-2025 | Voquezna |
| Seqirus USA INC | $51.59 | 2022-2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $48.65 | 2022-2024 | Gvoke Hypopen |
| Vertos Medical, INC. | $48.02 | 2024 | Mild Device Kit |
| Digestive Care, INC. | $47.51 | 2023 | Pertzye |
| Biohaven Pharmaceuticals, INC. | $46.41 | 2021 | |
| Radius Health, INC. | $44.05 | 2019-2025 | Tymlos |
| Zyla Life Sciences, INC. | $42.99 | 2019-2020 | |
| Ibsa Pharma INC. | $42.44 | 2019-2021 | |
| Tolmar, INC. | $40.54 | 2023-2025 | Jatenzo |
| Horizon Therapeutics Plc | $38.95 | 2019-2022 | |
| Boston Scientific Corporation | $38.33 | 2025 | General - Dbs |
| Bausch Health US, LLC | $36.73 | 2021-2025 | Wellbutrin |
| Phadia US INC. | $35.78 | 2019 | |
| Axonics, INC. | $34.41 | 2023 | Axonics |
| Optinose US, INC. | $29.58 | 2020 | |
| Althera Pharmaceuticals LLC | $29.55 | 2021-2022 | |
| Aytu Biopharma, INC. | $27.98 | 2019-2020 | |
| Sanofi Pasteur INC. | $25.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.57 | 2021-2023 | Eliquis |
| Alexion Pharmaceuticals, INC. | $24.37 | 2025 | Ultomiris |
| Genzyme Corporation | $23.33 | 2025 | |
| Averitas Pharma INC. | $20.20 | 2023 | Qutenza |
| Organon LLC | $19.38 | 2021 | |
| Clarus Therapeutics INC. | $17.62 | 2021 | |
| Hologic Sales and Service, LLC | $17.24 | 2025 | Thinprep 2000 Processor, Aptima |
| Linus Health, INC. | $15.07 | 2023 | |
| Currax Pharmaceuticals LLC | $14.00 | 2025 | Contrave |
| Ironwood Pharmaceuticals, INC | $13.23 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.85 | 2021 | |
| Hikma Pharmaceuticals USA | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Files listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.